Bioactive adrenomedullin and interleukin-6 in COVID-19: potential biomarkers of acute kidney injury and critical illness.
Acute Kidney Injury
Adrenomedullin
COVID-19
Interleukin-6
SARS-CoV-2
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
09 Feb 2024
09 Feb 2024
Historique:
received:
20
08
2023
accepted:
29
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
The aim of this study was to investigate whether bioactive adrenomedullin (bio-ADM) and interleukin-6 (IL-6) are related to acute kidney injury (AKI) and severe illness in COVID-19 patients. 153 patients with COVID-19 admitted to the emergency department (ED) were included. Blood samples were collected from each patient at admission. Bio-ADM and IL-6, as well as DPP3 and routinely measured markers were evaluated regarding the endpoints AKI (22/128 hospitalized patients) and a composite endpoint of admission to intensive care unit and/or in-hospital death (n = 26/153 patients). Bio-ADM and IL-6 were significantly elevated in COVID-19 patients with AKI compared to COVID-19 patients without AKI (each p < 0.001). According to ROC analyses IL-6 and bio-ADM had the largest AUC (0.84 and 0.81) regarding the detection of AKI. Furthermore, bio-ADM and IL-6 were significantly elevated in COVID-19 patients reaching the composite endpoint (each p < 0.001). Regarding the composite endpoint ROC analysis showed an AUC of 0.89 for IL-6 and 0.83 for bio-ADM in COVID-19 patients. In the multivariable logistic model bio-ADM and IL-6 presented as independent significant predictors regarding both endpoints AKI and the composite endpoint in COVID-19 patients (as well as creatinine regarding the composite endpoint; each p < 0.05), opposite to leukocytes, C-reactive protein (CRP) and dipeptidyl peptidase 3 (DPP3; each p = n.s.). Elevated levels of bio-ADM and IL-6 are associated with AKI and critical illness in patients with COVID-19. Therefore, both biomarkers may be potential tools in risk stratification in COVID-19 patients at presentation in the ED.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to investigate whether bioactive adrenomedullin (bio-ADM) and interleukin-6 (IL-6) are related to acute kidney injury (AKI) and severe illness in COVID-19 patients.
METHODS
METHODS
153 patients with COVID-19 admitted to the emergency department (ED) were included. Blood samples were collected from each patient at admission. Bio-ADM and IL-6, as well as DPP3 and routinely measured markers were evaluated regarding the endpoints AKI (22/128 hospitalized patients) and a composite endpoint of admission to intensive care unit and/or in-hospital death (n = 26/153 patients).
RESULTS
RESULTS
Bio-ADM and IL-6 were significantly elevated in COVID-19 patients with AKI compared to COVID-19 patients without AKI (each p < 0.001). According to ROC analyses IL-6 and bio-ADM had the largest AUC (0.84 and 0.81) regarding the detection of AKI. Furthermore, bio-ADM and IL-6 were significantly elevated in COVID-19 patients reaching the composite endpoint (each p < 0.001). Regarding the composite endpoint ROC analysis showed an AUC of 0.89 for IL-6 and 0.83 for bio-ADM in COVID-19 patients. In the multivariable logistic model bio-ADM and IL-6 presented as independent significant predictors regarding both endpoints AKI and the composite endpoint in COVID-19 patients (as well as creatinine regarding the composite endpoint; each p < 0.05), opposite to leukocytes, C-reactive protein (CRP) and dipeptidyl peptidase 3 (DPP3; each p = n.s.).
CONCLUSION
CONCLUSIONS
Elevated levels of bio-ADM and IL-6 are associated with AKI and critical illness in patients with COVID-19. Therefore, both biomarkers may be potential tools in risk stratification in COVID-19 patients at presentation in the ED.
Identifiants
pubmed: 38336628
doi: 10.1186/s12882-024-03486-1
pii: 10.1186/s12882-024-03486-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Informations de copyright
© 2024. The Author(s).
Références
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775 . Erratum in: JAMA. 2020 May 26;323(20):2098. PMID: 32320003; PMCID: PMC7177629.
doi: 10.1001/jama.2020.6775
pubmed: 32320003
pmcid: 7177629
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 . Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–38. https://doi.org/10.1016/j.kint.2020.03.005 . Epub 2020 Mar 20. PMID: 32247631; PMCID: PMC7110296.
doi: 10.1016/j.kint.2020.03.005
pubmed: 32247631
pmcid: 7110296
Ochoa-Callejero L, Pozo-Rodrigálvarez A, Martínez-Murillo R, et al. Author Correction: Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and less brain damage. Sci Rep. 2020;10:6283. https://doi.org/10.1038/s41598-020-62788-0 .
doi: 10.1038/s41598-020-62788-0
pubmed: 32269238
pmcid: 7142089
Schönauer R, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin - new perspectives of a potent peptide hormone. J Pept Sci. 2017;23(7–8):472–85. https://doi.org/10.1002/psc.2953 . (Epub 2017 Feb 2 PMID: 28150464).
doi: 10.1002/psc.2953
pubmed: 28150464
Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail. 2019;21(6):732–43. https://doi.org/10.1002/ejhf.1437 . (Epub 2019 Mar 6 PMID: 30843353).
doi: 10.1002/ejhf.1437
pubmed: 30843353
Takagi K, Levy B, Kimmoun A, Miró Ò, Duarte K, Asakage A, Blet A, Deniau B, Schulte J, Hartmann O, Cotter G, Davison BA, Gayat E, Mebazaa A. Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial. J Clin Med. 2021;10(19):4512. https://doi.org/10.3390/jcm10194512.PMID:34640526;PMCID:PMC8509471 .
doi: 10.3390/jcm10194512.PMID:34640526;PMCID:PMC8509471
pubmed: 34640526
pmcid: 8509471
Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, Gayat E, Hartmann O, Scigalla P, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, François B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF. AdrenOSS-1 study investigators. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018;22(1):354. https://doi.org/10.1186/s13054-018-2243-2 . PMID: 30583748; PMCID: PMC6305573.
doi: 10.1186/s13054-018-2243-2
pubmed: 30583748
pmcid: 6305573
Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, Cavana M, Tognoni G, Pesenti A, Gattinoni L, Masson S. Predicts Hemodynamic Support Requirement and Mortality During Sepsis. Chest. 2017;152(2):312–20. https://doi.org/10.1016/j.chest.2017.03.035 .
Lundberg OHM, Lengquist M, Spångfors M, Annborn M, Bergmann D, Schulte J, Levin H, Melander O, Frigyesi A, Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care. 2020;24(1):636. https://doi.org/10.1186/s13054-020-03351-1.PMID:33148300;PMCID:PMC7641835 .
doi: 10.1186/s13054-020-03351-1.PMID:33148300;PMCID:PMC7641835
pubmed: 33148300
pmcid: 7641835
Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347–52. https://doi.org/10.1093/intimm/dxq030 . (Epub 2010 Apr 21 PMID: 20410258).
doi: 10.1093/intimm/dxq030
pubmed: 20410258
Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, Choi WS. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019;19(1):968. https://doi.org/10.1186/s12879-019-4618-7.PMID:31718563;PMCID:PMC6852730 .
doi: 10.1186/s12879-019-4618-7.PMID:31718563;PMCID:PMC6852730
pubmed: 31718563
pmcid: 6852730
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84. https://doi.org/10.1159/000339789 . (Epub 2012 Aug 7 PMID: 22890468).
doi: 10.1159/000339789
pubmed: 22890468
Weber J, Sachse J, Bergmann S, Sparwaßer A, Struck J, Bergmann A. Sandwich Immunoassay for Bioactive Plasma Adrenomedullin. J Appl Lab Med. 2017;2(2):222–33. https://doi.org/10.1373/jalm.2017.023655 .
doi: 10.1373/jalm.2017.023655
pubmed: 32630976
Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014;18(1):R34. https://doi.org/10.1186/cc13731 . (PMID:24533868;PMCID:PMC4056312).
doi: 10.1186/cc13731
pubmed: 24533868
pmcid: 4056312
Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples. J Appl Lab Med. 2019;3(6):943–53. https://doi.org/10.1373/jalm.2018.027995 . (Epub 2018 Nov 30 PMID: 31639686).
doi: 10.1373/jalm.2018.027995
pubmed: 31639686
Blet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X, Chousterman BG, Gayat E, Hartmann O, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, François B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF, Mebazaa A. AdrenOSS-1 Study Investigators. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care. 2021;25(1):61. https://doi.org/10.1186/s13054-021-03471-2 . PMID: 33588925; PMCID: PMC7885215.
doi: 10.1186/s13054-021-03471-2
pubmed: 33588925
pmcid: 7885215
Deniau B, Picod A, Van Lier D, Vaittinada Ayar P, Santos K, Hartmann O, Gayat E, Mebazaa A, Blet A, Azibani F. High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Br J Anaesth. 2022;128(2):e54–7. https://doi.org/10.1016/j.bja.2021.11.021 . (Epub 2021 Dec 8 PMID: 34895716).
doi: 10.1016/j.bja.2021.11.021
pubmed: 34895716
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45 (PMID: 3203132).
doi: 10.2307/2531595
pubmed: 3203132
Staudner ST, Leininger SB, Vogel MJ, et al. Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates. Clin Exp Med. 2023. https://doi.org/10.1007/s10238-023-01193-z .
doi: 10.1007/s10238-023-01193-z
pubmed: 37733154
pmcid: 10725357
Simon TP, Stoppe C, Breuer T, Stiehler L, Dreher M, Kersten A, Kluge S, Karakas M, Zechendorf E, Marx G, Martin L. Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. J Clin Med. 2021;10(8):1667. https://doi.org/10.3390/jcm10081667 . (PMID:33924637;PMCID:PMC8069401).
doi: 10.3390/jcm10081667
pubmed: 33924637
pmcid: 8069401
van Lier D, Deniau B, Santos K, Hartmann O, Dudoignon E, Depret F, Plaud B, Laterre PF, Mebazaa A, Pickkers P. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study. ERJ Open Res. 2023;9(1):00342–2022. https://doi.org/10.1183/23120541.00342-2022 . (PMID:36628268;PMCID:PMC9571166).
doi: 10.1183/23120541.00342-2022
pubmed: 36628268
pmcid: 9571166
Papasidero ID, Valli G, Marin D, Del Sasso A, De Magistris A, Cennamo E, Casalboni S, De Marco F, Rocchi R, Ndogmo Beumo B, Cusani V, Gaudio M, Hartmann O, Bergman A, Ruggieri MP, Di Somma S. Utility of Measuring Circulating Bio-Adrenomedullin and Proenkephalin for 30-Day Mortality Risk Prediction in Patients with COVID-19 and Non-COVID-19 Interstitial Pneumonia in the Emergency Department. Medicina (Kaunas). 2022;58(12):1852. https://doi.org/10.3390/medicina58121852 . (PMID:36557054;PMCID:PMC9782909).
doi: 10.3390/medicina58121852
pubmed: 36557054
Bauer W, Weber M, Diehl-Wiesenecker E, Galtung N, Prpic M, Somasundaram R, Tauber R, Schwenk JM, Micke P, Kappert K. Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection. Viruses. 2021;13(12):2456. https://doi.org/10.3390/v13122456 . (PMID:34960725;PMCID:PMC8706135).
doi: 10.3390/v13122456
pubmed: 34960725
pmcid: 8706135
Hupf J, Mustroph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit Care. 2020;24(1):527. https://doi.org/10.1186/s13054-020-03246-1 . (PMID:32859259;PMCID:PMC7453369).
doi: 10.1186/s13054-020-03246-1
pubmed: 32859259
pmcid: 7453369
Minieri M, Di Lecce VN, Lia MS, Maurici M, Bernardini S, Legramante JM. Role of MR-proADM in the risk stratification of COVID-19 patients assessed at the triage of the Emergency Department. Crit Care. 2021;25(1):407. https://doi.org/10.1186/s13054-021-03834-9 . (PMID:34836547;PMCID:PMC8619649).
doi: 10.1186/s13054-021-03834-9
pubmed: 34836547
pmcid: 8619649
García de Guadiana-Romualdo L, Martínez Martínez M, Rodríguez Mulero MD, Esteban-Torrella P, Hernández Olivo M, Alcaraz García MJ, Campos-Rodríguez V, Sancho-Rodríguez N, Galindo Martínez M, Alcaraz A, Ros Braquehais MS, Báguena Perez-Crespo C, Ramos Arenas V, Tomás Jiménez C, Consuegra-Sánchez L, Conesa-Hernandez A, Piñera-Salmerón P, Bernal-Morell E. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int J Infect Dis. 2021;111:211–8. https://doi.org/10.1016/j.ijid.2021.08.058 . Epub 2021 Aug 28. PMID: 34461254; PMCID: PMC8400460.
doi: 10.1016/j.ijid.2021.08.058
pubmed: 34461254
pmcid: 8400460
Moore N, Williams R, Mori M, Bertolusso B, Vernet G, Lynch J, Philipson P, Ledgerwood T, Kidd SP, Thomas C, Garcia-Arias V, Young M, Saeed K, Gordon K, Cortes N. Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting. J Clin Pathol. 2022 Jan 7:jclinpath-2021–207750. https://doi.org/10.1136/jclinpath-2021-207750 . Epub ahead of print. PMID: 34996755; PMCID: PMC8761594.
Indirli R, Bandera A, Valenti L, Ceriotti F, Di Modugno A, Tettamanti M, Gualtierotti R, Peyvandi F, Montano N, Blasi F, Costantino G, Resi V, Orsi E, Arosio M, Mantovani G, Ferrante E. COVID-19 Network Working Group. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. Eur J Clin Invest. 2022;7:e13753. https://doi.org/10.1111/eci.13753 . Epub ahead of print. PMID: 35128648.
doi: 10.1111/eci.13753
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020 Apr 6;:]. Intensive Care Med. 2020;46(5):846–848. https://doi.org/10.1007/s00134-020-05991-x
Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. Published 2020 May 1. https://doi.org/10.3389/fimmu.2020.00827
Xia P, Wen Y, Duan Y, Su H, Cao W, Xiao M, Ma J, Zhou Y, Chen G, Jiang W, Wu H, Hu Y, Xu S, Cai H, Liu Z, Zhou X, Du B, Wang J, Li T, Yan X, Chen L, Liang Z, Zhang S, Zhang C, Qin Y, Wang G, Li X. Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort. J Am Soc Nephrol. 2020 Sep;31(9):2205–2221. https://doi.org/10.1681/ASN.2020040426 . Epub 2020 Aug 21. PMID: 32826326; PMCID: PMC7461691.